Ski-Doo, a brand of BRP Inc., has awarded more than 50 snowmobiling clubs up to $5,000 each through its 2026 Snow PASS grants to help maintain trails and preserve winter access. Since its launch, the program has contributed over CAD $1.5 million to community-led projects focused on trail infrastructure, access preservation, and volunteer support. This initiative highlights Ski-Doo's commitment to supporting grassroots organizations and volunteers who keep snowmobiling thriving across North America. The grants were announced at the Hay Days event, emphasizing the importance of pre-season trail work for a full riding season.
The Ski-Doo Snow PASS Program's recent funding awards to snowmobiling clubs provide context for consumer cyclical sector activity on Pluang. For readers following this sector, here is Pluang's market snapshot as of Sep 16, 2026 02:31 WIB: out of 105 priced US stocks, 10 rose and 95 fell. Notable price changes include NEGG at USD 13.55 with a -6.03% change, DKS at USD 123.05 down -5.90%, and BIRD at USD 2.37 down -5.58%.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
